PBYI up +1.27% percent right now. $PBYI High is at 243.63 and the Low 235.70 with current volume of 110,389.
Recent News posted below.
PBYI Puma Biotechnology Recent Headline News
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 110.15 (-2.62), ABMD: 32.65 (+0.52), JNJ: 108.65 (+0.45), AMGN: 162.11 (+1.86), EXAS: 22.54 (-0.28), ARAY: 6.85 (unch), HOLX: 26.43 (+0.22), PBYI: 238.29 (+1.40)
Research and Markets: Puma Biotechnology's Neratinib (HER2-Positive Breast Cancer Treatment) Report 2014 with Forecasts and Market Analysis to 2023
Business Wire - Mon Oct 20, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbnmvd/neratinib) has announced the addition of the "Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.
PBYI: 238.29 (+1.40)
Puma Biotechnology's Neratinib (HER2-Positive Breast Cancer Treratment) Report 2014 with Forecasts and Market Analysis to 2023
M2 - Mon Oct 20, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6cmpxn/neratinib) has announced the addition of the "Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering. Puma Biotechnology's neratinib is an orally-administered TKI that binds irreversibly, targeting HER1, HER2, and HER4. Neratinib inhibits HER2 at a different site than the currently marketed HER2-targeted therapies, which Puma believes will make it effective in patients who have developed resistance to these other treatments. Scope - Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Neratinib including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Neratinib for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity 7 Pipeline Assessment 8 Neratinib 9 Appendix For more information visit http://www.researchandmarkets.com/research/6cmpxn/neratinib
PBYI: 238.29 (+1.40)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 108.65 (+0.45), PTLA: 27.26 (-0.13), PFE: 30.16 (+0.24), BMY: 58.57 (+0.25), PRTA: 22.45 (-0.11), PBYI: 238.29 (+1.40)
Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore!
at The Street - Fri Oct 10, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GILD: 107.47 (+1.02), ARWR: 6.43 (+0.37), PBYI: 238.29 (+1.40), KERX: 16.47 (-0.26)
Positive Study Results, CSR Activities, and New Aircraft Livery - Research Reports on Puma Biotechnology, HCA Holdings, United Technologies, Boeing and Caterpillar
PR Newswire - Wed Oct 01, 7:30AM CDT
Today, Analysts Review released its research reports regarding Puma Biotechnology, Inc. (NYSE: PBYI), HCA Holdings, Inc. (NYSE: HCA), United Technologies Corporation (NYSE: UTX), The Boeing Company (NYSE: BA) and Caterpillar Inc. (NYSE: CAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6886-100free.
HCA: 67.20 (+1.45), UTX: 108.90 (-0.18), CAT: 102.29 (+0.53), BA: 124.71 (+0.26), PBYI: 238.29 (+1.40)
Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Business Wire - Mon Sep 29, 5:07AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) with HER2 mutations was presented today as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain. The presentation was entitled "Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study."
PBYI: 238.29 (+1.40)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 107.49 (+1.04), ACHN: 12.36 (+2.25), RCPT: 109.14 (-0.10), PTCT: 40.83 (+0.59), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
KOG: 10.24 (-0.22), ISIS: 46.24 (+1.65), WEX: 114.91 (+1.08), VXX: 28.02 (-1.01), ITMN: 73.89 (-0.02), IWM: 116.60 (-0.11), PBYI: 238.29 (+1.40)
NYSE stocks posting largest percentage increases
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
GLP: 41.31 (+2.41), DHT: 6.35 (-0.13), BNNY: 45.97 (-0.01), DRL: 5.28 (-0.22), WMS: 22.00 (-0.24), CSLT: 11.57 (-0.40), GCAP: 8.93 (-0.09), IMPV: 42.96 (+0.43), PANW: 109.46 (+2.44), MBLY: 46.07 (-0.70), PBYI: 238.29 (+1.40)
Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Business Wire - Wed Sep 03, 7:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain. The presentation entitled "Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study" will occur on September 29, 2014.
PBYI: 238.29 (+1.40)
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), RCPT: 109.14 (-0.10), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
GILD: 107.49 (+1.04), ACHN: 12.36 (+2.25), MRK: 58.80 (-0.54), ITMN: 73.89 (-0.02), RCPT: 109.14 (-0.10), ICPT: 177.30 (+4.71), TEVA: 58.05 (+0.35), PBYI: 238.29 (+1.40), CELG: 107.52 (+1.07)
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
KITE: 42.59 (-3.40), ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), ALXN: 193.78 (-0.03), PBYI: 238.29 (+1.40), FOLD: 6.24 (+0.52), CELG: 107.52 (+1.07)
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report).
ACHN: 12.36 (+2.25), PBYI: 238.29 (+1.40)
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
BIIB: 324.13 (+3.38), PCYC: 132.79 (-0.70), GILD: 107.49 (+1.04), ITMN: 73.89 (-0.02), PBYI: 238.29 (+1.40), CELG: 107.52 (+1.07)
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
AGN: 195.73 (-0.27), HCA: 67.20 (+1.45), VRX: 127.32 (+1.21), SLXP: 94.00 (+2.53), PBYI: 238.29 (+1.40)
Recent News posted below.
PBYI Puma Biotechnology Recent Headline News
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 110.15 (-2.62), ABMD: 32.65 (+0.52), JNJ: 108.65 (+0.45), AMGN: 162.11 (+1.86), EXAS: 22.54 (-0.28), ARAY: 6.85 (unch), HOLX: 26.43 (+0.22), PBYI: 238.29 (+1.40)
Research and Markets: Puma Biotechnology's Neratinib (HER2-Positive Breast Cancer Treatment) Report 2014 with Forecasts and Market Analysis to 2023
Business Wire - Mon Oct 20, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbnmvd/neratinib) has announced the addition of the "Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.
PBYI: 238.29 (+1.40)
Puma Biotechnology's Neratinib (HER2-Positive Breast Cancer Treratment) Report 2014 with Forecasts and Market Analysis to 2023
M2 - Mon Oct 20, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6cmpxn/neratinib) has announced the addition of the "Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering. Puma Biotechnology's neratinib is an orally-administered TKI that binds irreversibly, targeting HER1, HER2, and HER4. Neratinib inhibits HER2 at a different site than the currently marketed HER2-targeted therapies, which Puma believes will make it effective in patients who have developed resistance to these other treatments. Scope - Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Neratinib including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Neratinib for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity 7 Pipeline Assessment 8 Neratinib 9 Appendix For more information visit http://www.researchandmarkets.com/research/6cmpxn/neratinib
PBYI: 238.29 (+1.40)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 108.65 (+0.45), PTLA: 27.26 (-0.13), PFE: 30.16 (+0.24), BMY: 58.57 (+0.25), PRTA: 22.45 (-0.11), PBYI: 238.29 (+1.40)
Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore!
at The Street - Fri Oct 10, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GILD: 107.47 (+1.02), ARWR: 6.43 (+0.37), PBYI: 238.29 (+1.40), KERX: 16.47 (-0.26)
Positive Study Results, CSR Activities, and New Aircraft Livery - Research Reports on Puma Biotechnology, HCA Holdings, United Technologies, Boeing and Caterpillar
PR Newswire - Wed Oct 01, 7:30AM CDT
Today, Analysts Review released its research reports regarding Puma Biotechnology, Inc. (NYSE: PBYI), HCA Holdings, Inc. (NYSE: HCA), United Technologies Corporation (NYSE: UTX), The Boeing Company (NYSE: BA) and Caterpillar Inc. (NYSE: CAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6886-100free.
HCA: 67.20 (+1.45), UTX: 108.90 (-0.18), CAT: 102.29 (+0.53), BA: 124.71 (+0.26), PBYI: 238.29 (+1.40)
Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer
Business Wire - Mon Sep 29, 5:07AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) with HER2 mutations was presented today as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain. The presentation was entitled "Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study."
PBYI: 238.29 (+1.40)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 107.49 (+1.04), ACHN: 12.36 (+2.25), RCPT: 109.14 (-0.10), PTCT: 40.83 (+0.59), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
KOG: 10.24 (-0.22), ISIS: 46.24 (+1.65), WEX: 114.91 (+1.08), VXX: 28.02 (-1.01), ITMN: 73.89 (-0.02), IWM: 116.60 (-0.11), PBYI: 238.29 (+1.40)
NYSE stocks posting largest percentage increases
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
GLP: 41.31 (+2.41), DHT: 6.35 (-0.13), BNNY: 45.97 (-0.01), DRL: 5.28 (-0.22), WMS: 22.00 (-0.24), CSLT: 11.57 (-0.40), GCAP: 8.93 (-0.09), IMPV: 42.96 (+0.43), PANW: 109.46 (+2.44), MBLY: 46.07 (-0.70), PBYI: 238.29 (+1.40)
Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014
Business Wire - Wed Sep 03, 7:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain. The presentation entitled "Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study" will occur on September 29, 2014.
PBYI: 238.29 (+1.40)
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), RCPT: 109.14 (-0.10), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
GILD: 107.49 (+1.04), ACHN: 12.36 (+2.25), MRK: 58.80 (-0.54), ITMN: 73.89 (-0.02), RCPT: 109.14 (-0.10), ICPT: 177.30 (+4.71), TEVA: 58.05 (+0.35), PBYI: 238.29 (+1.40), CELG: 107.52 (+1.07)
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
KITE: 42.59 (-3.40), ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), ALXN: 193.78 (-0.03), PBYI: 238.29 (+1.40), FOLD: 6.24 (+0.52), CELG: 107.52 (+1.07)
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report). ACHN: 12.36 (+2.25), PBYI: 238.29 (+1.40)
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
BIIB: 324.13 (+3.38), PCYC: 132.79 (-0.70), GILD: 107.49 (+1.04), ITMN: 73.89 (-0.02), PBYI: 238.29 (+1.40), CELG: 107.52 (+1.07)
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
ACHN: 12.36 (+2.25), ITMN: 73.89 (-0.02), ICPT: 177.30 (+4.71), PBYI: 238.29 (+1.40)
Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
AGN: 195.73 (-0.27), HCA: 67.20 (+1.45), VRX: 127.32 (+1.21), SLXP: 94.00 (+2.53), PBYI: 238.29 (+1.40)
